ArticleClinical and experimental pediatrics2020
Treatment of refractory IgA vasculitis with dapsone: a systematic review.
Article in Clinical and experimental pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- National recommendations for the management of children and young people with IgA vasculitis: a best available evidence, group agreement-based approach.Archives of disease in childhood · 2024Guideline
- Gastrointestinal manifestations and pathogenesis in childhood immunoglobulin A vasculitis.Frontiers in pediatrics · 2024Review
- Immunoglobulin A vasculitis nephritis: Current understanding of pathogenesis and treatment.World journal of nephrology · 2023Review
- A case series on recurrent and persisting IgA vasculitis (Henoch Schonlein purpura) in children.Pediatric rheumatology online journal · 2023Article
- IgA Vasculitis in Japanese Patients Harboring MEFV Mutations: A Case Report and Review of the Literature.Cureus · 2023Article
- Successful treatment of refractory IgA vasculitis with tofacitinib.JAAD case reports · 2022Article
- Management of IgA Vasculitis with Nephritis.Paediatric drugs · 2021Review
- IgA Vasculitis: Etiology, Treatment, Biomarkers and Epigenetic Changes.International journal of molecular sciences · 2021Review
- Hemorrhagic rash on the legs.JAAD case reports · 2021Article
- [Diagnosis and treatment of vasculitic ulcerations].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2020Review
- Dapsone: a steroid-sparing drug for refractory immunoglobulin A vasculitis?Clinical and experimental pediatrics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA vasculitis, formerly known as Henoch-Schönlein purpura, is a systemic IgA-mediated vasculitis of the small vessels commonly seen in children. The natural history of IgA vasculitis is generally self-limiting; however, one-third of patients experience symptom recurrence and a refractory course. This systematic review examined the use of dapsone in refractory IgA vasculitis cases. A literature search of PubMed databases retrieved 13 articles published until June 14, 2018. The most common clinical feature was a palpable rash (100% of patients), followed by joint pain (69.2%). Treatment response within 1-2 days was observed in 6 of 26 patients (23.1%) versus within 3-7 days in 17 patients (65.4%). Relapse after treatment discontinuation was reported in 17 patients (65.4%) but not in 3 patients (11.5 %). Four of the 26 patients (15.4%) reported adverse effects of dapsone including arthralgia (7.7%), rash (7.7%), and dapsone hypersensitivity syndrome (3.8%). Our findings suggest that dapsone may affect refractory IgA vasculitis. Multicenter randomized placebo-controlled trials are necessary to determine the standard dosage of dapsone at initial or tapering of treatment in IgA vasculitis patients and evaluate whether dapsone has a significant benefit versus steroids or other medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.